
    
      Collection of additional safety and efficacy data with deferasirox film-coated tablet (FCT)
      in patients who had completed study CICL670F2201

        -  Provide patients who completed 24 weeks of treatment in the core study, CICL670F2201,
           the possibility to have additional treatment with the deferasirox FCT.

        -  Collect additional longer term data on the safety and the tolerability of the
           deferasirox FCT.

        -  Collect efficacy data on the deferasirox FCT in reduction or maintenance of iron burden
           as measured by serum ferritin level.
    
  